Short answer
Definitive Healthcare Corp. (DH) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $55M (down 9.0% year over year) with net income of −$4M.
Q3 2026 key financials · XBRL
- Revenue
- $55M
- −9.0% YoY · −1.0% QoQ
- Net income
- −$4M
- +73.8% YoY · +28.2% QoQ
- Operating margin
- -9.1%
- Gross margin
- 77.3%
- EPS (diluted)
- −$0.03
- +80.0% YoY · +40.0% QoQ
Source: XBRL data from the Definitive Healthcare Corp. (DH) Q3 2026 10-Q on SEC EDGAR. USD.
Definitive Healthcare Corp. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $54.7M, down 9% YoY from $60.0M, driven by $5.5M lower subscription revenue
- Gross margin 77.3% vs 76.6% YoY, with gross profit $42.2M vs $46.0M
- Existing-customer revenue fell $8.4M, partially offset by $3.0M from new customers
- Cash $177.1M plus $12.8M short-term investments, with $34.4M operating cash flow through nine months
- 2026 outlook: negative revenue growth, pressured by churn, elongated deal cycles, and sales execution challenges
Risk Factors
- Nasdaq delisting risk: bid price fell below $1.00 for 30 consecutive business days, though compliance was regained October 30, 2026
- Acquisition proposal risk: Advent submitted a non-binding indication of interest on September 2, 2026
- Strategic transaction risk: proposal uncertainty could divert management time and resources
- Legal risk: litigation connected to the Advent proposal could generate substantial costs
- Financing risk: potential Nasdaq delisting could limit access to debt and equity financing
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Definitive Healthcare Corp. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.